Zobrazeno 1 - 10
of 54
pro vyhledávání: '"Willem A. Bax"'
Autor:
Niekbachsh Mohammadnia, Jan Los, Tjerk S. J. Opstal, Aernoud T. L. Fiolet, John W. Eikelboom, Arend Mosterd, Stefan M. Nidorf, Charley A. Budgeon, Jan G. P. Tijssen, Peter L. Thompson, Cees J. Tack, Suat Simsek, Willem A. Bax, Jan H. Cornel, Saloua El Messaoudi
Publikováno v:
Frontiers in Cardiovascular Medicine, Vol 10 (2023)
IntroductionDespite optimal treatment, patients with chronic coronary artery disease (CAD) and diabetes mellitus (DM) are at high risk of cardiovascular events, emphasizing the need for new treatment options. The Low-Dose Colchicine 2 (LoDoCo2) trial
Externí odkaz:
https://doaj.org/article/22bccdd36673494589e80219438b8e8b
Publikováno v:
BMC Health Services Research, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background Healthcare rationing can be defined as withholding beneficial care for cost reasons. One form in particular, hidden bedside rationing, is problematic because it may result in conflicting loyalties for physicians, unfair inequality
Externí odkaz:
https://doaj.org/article/0710c6edf2f6486c8793bf8c0a0a4c21
Publikováno v:
European Heart Journal – Digital Health, 3, 4, pp. 578-586
European Heart Journal – Digital Health, 3, 578-586
European Heart Journal – Digital Health, 3, 578-586
AimsFamilial hypercholesterolaemia (FH) is a disorder of LDL cholesterol clearance, resulting in increased risk of cardiovascular disease. Recently, we developed a Dutch Lipid Clinic Network (DLCN) criteria-based algorithm to facilitate FH detection
Autor:
Ursula W. de Ruijter, Z. L. Rana Kaplan, Wichor M. Bramer, Frank Eijkenaar, Daan Nieboer, Agnes van der Heide, Hester F. Lingsma, Willem A. Bax
Publikováno v:
Journal of General Internal Medicine. 37(7):1763-1770
Background In an effort to improve both quality of care and cost-effectiveness, various care-management programmes have been developed for high-need high-cost (HNHC) patients. Early identification of patients at risk of becoming HNHC (i.e. case findi
Autor:
Amber van Broekhoven, Niekbachsh Mohammadnia, Max J. M. Silvis, Jonathan Los, Aernoud T. L. Fiolet, Tjerk S. J. Opstal, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Charley A. Budgeon, Elizabeth Byrnes, Willem A. Bax, Jan G. P. Tijssen, Dominique P. V. de Kleijn, Peter L. Thompson, Saloua El Messaoudi, Jan H. Cornel
Publikováno v:
Clinical drug investigation, 42(11), 977-985. Adis International Ltd
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Clinical Drug Investigation, 42, 977-985
Clinical Drug Investigation, 42, 11, pp. 977-985
Contains fulltext : 288089.pdf (Publisher’s version ) (Open Access) BACKGROUND AND OBJECTIVE: The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in pati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a7e75f557f8750b00f611a1192bac17
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
https://research.vumc.nl/en/publications/94450c2a-4c60-47b0-a72e-c9b9f640b416
Autor:
Amber, van Broekhoven, Niekbachsh, Mohammadnia, Max J M, Silvis, Jonathan, Los, Aernoud T L, Fiolet, Tjerk S J, Opstal, Arend, Mosterd, John W, Eikelboom, Stefan M, Nidorf, Charley A, Budgeon, Elizabeth, Byrnes, Willem A, Bax, Jan G P, Tijssen, Dominique P V, de Kleijn, Peter L, Thompson, Saloua, El Messaoudi, Jan H, Cornel
Publikováno v:
Clinical drug investigation. 42(11)
The Low-Dose Colchicine-2 (LoDoCo2) trial showed that 2-4 years exposure to colchicine 0.5 mg once daily reduced the risk of cardiovascular events in patients with chronic coronary artery disease. The potential effect of years-long exposure to colchi
Autor:
Tjerk S.J. Opstal, Aernoud T.L. Fiolet, Amber van Broekhoven, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Michiel Duyvendak, J.W. Martijn van Eck, Eugène A. van Beek, Frank den Hartog, Charley A. Budgeon, Willem A. Bax, Jan G.P. Tijssen, Saloua El Messaoudi, Jan H. Cornel, S.M. Nidorf, X.F. Xu, M.A. Ireland, D. Latchem, A. Whelan, R. Hendriks, P. Salkani, I.W. Tan, A.G. Thompson, A.M. Morton, B.E. Hockings, P.L. Thompson, B. King, J.H. Cornel, H. Bakker-Lohmeijer, A. Mosterd, P. Bunschoten, S.H.K. The, S. van der Kooi, T. Lenderink, R.G.J.L. Lardinois, P.A.M. Hoogslag, A. de Vos, A. Jerzewski, S. Jansen, P.R. Nierop, M. van der Knaap, H.P. Swart, R. Kingma, J. Schaap, L.B. Blom, A.F.M. Kuijper, E. Bayraktar-Verver, M.W.J. van Hessen, W.C.T.C. Engelen, J.W.M. van Eck, N. van der Ven-Elzebroek, J.M.C. van Hal, I.M.J. Drost, F.R. den Hartog, D. van Wijk, E. van Beek, C. van der Horst, G.L. Bartels, M. Hendriks, C. de Nooijer, C. Welten, E. Ronner, A. Dijkshoorn, F.J. Prins, R.N.A. Rutten, D.P.W. Beele, I. Hendriks, A. van der Sluis, E.A. Badings, I.C.D. Westendorp, A. Melein, Tj.J. Römer, P. Bruines, R. van de Wal, I. Leenders - van Lieshout, M.E.W. Hemels, K. Meinen-Werner, M.R. de Groot, G. Post, M.W.C. Mulder, S. Stuij, E. van Nes, P. Luyten, J. Plomp, S.V. Veldmeijer, M.J. Asselman, P.A. Scholtus
Publikováno v:
Journal of the American College of Cardiology, 78, 859-866
Journal of the American College of Cardiology, 78(9), 859-866. Elsevier USA
Journal of the American College of Cardiology, 78, 9, pp. 859-866
LoDoCo2 Trial Investigators 2021, ' Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome ', Journal of the American College of Cardiology, vol. 78, no. 9, pp. 859-866 . https://doi.org/10.1016/j.jacc.2021.06.037
Journal of the American College of Cardiology, 78(9), 859-866. Elsevier USA
Journal of the American College of Cardiology, 78, 9, pp. 859-866
LoDoCo2 Trial Investigators 2021, ' Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome ', Journal of the American College of Cardiology, vol. 78, no. 9, pp. 859-866 . https://doi.org/10.1016/j.jacc.2021.06.037
Background: Colchicine reduces risk of cardiovascular events in patients post–myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acut
Autor:
Stefan M, Nidorf, Aernoud T L, Fiolet, Arend, Mosterd, John W, Eikelboom, Astrid, Schut, Tjerk S J, Opstal, Salem H K, The, Xiao-Fang, Xu, Mark A, Ireland, Timo, Lenderink, Donald, Latchem, Pieter, Hoogslag, Anastazia, Jerzewski, Peter, Nierop, Alan, Whelan, Randall, Hendriks, Henk, Swart, Jeroen, Schaap, Aaf F M, Kuijper, Maarten W J, van Hessen, Pradyot, Saklani, Isabel, Tan, Angus G, Thompson, Allison, Morton, Chris, Judkins, Willem A, Bax, Maurits, Dirksen, Marco, Alings, Graeme J, Hankey, Charley A, Budgeon, Jan G P, Tijssen, Jan H, Cornel, Peter L, Thompson, Karen, Youl
Publikováno v:
LoDoCo2 Trial Investigators 2020, ' Colchicine in patients with chronic coronary disease ', New England Journal of Medicine, vol. 383, no. 19, pp. 1838-1847 . https://doi.org/10.1056/NEJMoa2021372
The New England Journal of Medicine, 383, 1838-1847
The New England Journal of Medicine, 383, 19, pp. 1838-1847
New England journal of medicine, 383(19), 1838-1847. Massachussetts Medical Society
New England Journal of Medicine, 383(19), 1838-1847. Massachussetts Medical Society
The New England Journal of Medicine, 383, 1838-1847
The New England Journal of Medicine, 383, 19, pp. 1838-1847
New England journal of medicine, 383(19), 1838-1847. Massachussetts Medical Society
New England Journal of Medicine, 383(19), 1838-1847. Massachussetts Medical Society
Evidence from a recent trial has shown that the antiinflammatory effects of colchicine reduce the risk of cardiovascular events in patients with recent myocardial infarction, but evidence of such a risk reduction in patients with chronic coronary dis
Autor:
Tjerk S.J. Opstal, Amber van Broekhoven, Aernoud T.L. Fiolet, Arend Mosterd, John W. Eikelboom, Stefan M. Nidorf, Peter L. Thompson, Charley A. Budgeon, Louis Bartels, Ron de Nooijer, Willem A. Bax, Jan G.P. Tijssen, Saloua El Messaoudi, Jan H. Cornel
Publikováno v:
Circulation, 145, 8, pp. 626-628
Circulation, 145(8), 626-628. Lippincott Williams and Wilkins
Circulation, 145, 626-628
Circulation, 145(8), 626-628. Lippincott Williams and Wilkins
Circulation, 145, 626-628
Contains fulltext : 249988.pdf (Publisher’s version ) (Closed access)
Publikováno v:
Circulation. 144
Introduction: Familial hypercholesterolemia (FH) is a genetic disorder resulting in elevated LDL-C levels and increased risk of cardiovascular disease. Algorithms have been developed to facilitate FH detection. We previously developed a continuous, e